Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,114 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03539536 | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 270 | AbbVieINDUSTRY | 26 | Nov 5, 2025 | clinicaltrials |
| NCT04245839 | A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)(TRANSCEND FL) | active not recruiting | Phase 2 | 276 | CelgeneINDUSTRY | 10 | Nov 5, 2025 |
| clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT03822117 | Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | terminated | Phase 2 | 111 | Incyte CorporationINDUSTRY | 11 | Nov 4, 2025 | clinicaltrials |
| NCT04003610 | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | terminated | Phase 2 | 7 | Incyte CorporationINDUSTRY | 16 | Nov 4, 2025 | clinicaltrials |
| NCT04958785 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer(ELEVATE TNBC) | terminated | Phase 2 | 92 | Gilead SciencesINDUSTRY | 6 | Nov 4, 2025 | clinicaltrials |
| NCT03620643 | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours(ROLo) | completed | Phase 2 | 33 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05456685 | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer | active not recruiting | Phase 2 | 125 | AbbVieINDUSTRY | 6 | Oct 28, 2025 | clinicaltrials |
| NCT05091346 | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 89 | Eisai Inc.INDUSTRY | 4 | Oct 24, 2025 | clinicaltrials |
| NCT02959437 | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | terminated | Phase 1 / Phase 2 | 70 | Incyte CorporationINDUSTRY | 3 | Oct 21, 2025 | clinicaltrials |
| NCT04497116 | Study of RP-3500, Camonsertib, in Advanced Solid Tumors(TRESR) | completed | Phase 1 / Phase 2 | 276 | Repare TherapeuticsINDUSTRY | 4 | Oct 21, 2025 | clinicaltrials |
| NCT04660812 | An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.(ARC-9) | completed | Phase 1 / Phase 2 | 227 | Arcus Biosciences, Inc.INDUSTRY | 6 | Oct 20, 2025 | clinicaltrials |
| NCT04189445 | Futibatinib in Patients With Specific FGFR Aberrations | terminated | Phase 2 | 115 | Taiho Oncology, Inc.INDUSTRY | 15 | Oct 8, 2025 | clinicaltrials |
| NCT04501614 | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 11 | TakedaINDUSTRY | 15 | Oct 2, 2025 | clinicaltrials |
| NCT04260126 | Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC(VERSATILE002) | completed | Phase 2 | 95 | PDS Biotechnology Corp.INDUSTRY | 4 | Oct 1, 2025 | clinicaltrials |
| NCT05148546 | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer(NESCIO) | active not recruiting | Phase 2 | 69 | The Netherlands Cancer InstituteOTHER | 2 | Sep 30, 2025 | clinicaltrials |
| NCT05358808 | ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)(ACHIEVE) | terminated | Phase 2 | 16 | TC BiopharmINDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03075423 | Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC | completed | Phase 2 | 316 | Goethe UniversityOTHER | 7 | Sep 26, 2025 | clinicaltrials |
| NCT03184571 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 99 | BerGenBio ASAINDUSTRY | 4 | Sep 25, 2025 | clinicaltrials |
| NCT07192588 | A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer(GuARD) | active not recruiting | Phase 2 | 273 | Graegis Pharmaceuticals LtdINDUSTRY | 2 | Sep 25, 2025 | clinicaltrials |
| NCT03731260 | (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis | active not recruiting | Phase 2 | 251 | Blueprint Medicines CorporationINDUSTRY | 13 | Sep 23, 2025 | clinicaltrials |
| NCT05223920 | An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) | completed | Phase 2 | 81 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 7 | Sep 22, 2025 | clinicaltrials |
| NCT02863055 | Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma(NEMO) | terminated | Phase 2 | 37 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Sep 19, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05658640 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies(HEM-iSMART D) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 15 | Sep 16, 2025 | clinicaltrials |
| NCT05745714 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART C) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT05751044 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART B) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT04466891 | A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers(HERIZON-BTC-01) | completed | Phase 2 | 87 | Jazz PharmaceuticalsINDUSTRY | 9 | Sep 15, 2025 | clinicaltrials |
| NCT02500407 | A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 713 | Genentech, Inc.INDUSTRY | 7 | Sep 12, 2025 | clinicaltrials |
| NCT05678257 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | terminated | Phase 2 | 180 | NuCana plcOTHER | 6 | Sep 12, 2025 | clinicaltrials |
| NCT05845814 | A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) | active not recruiting | Phase 1 / Phase 2 | 390 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2025 | clinicaltrials |
| NCT03470922 | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma(RELATIVITY-047) | active not recruiting | Phase 2 / Phase 3 | 714 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 9, 2025 | clinicaltrials |
| NCT07161778 | A Trial of Triamcinolone With a GnRH Analog for Castration Resistant Prostate Cancer(TRICREST) | completed | Phase 2 | 55 | Barts & The London NHS TrustOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05372354 | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 260 | Bristol-Myers SquibbINDUSTRY | 5 | Sep 5, 2025 | clinicaltrials |
| NCT03525678 | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody | completed | Phase 2 | 221 | GlaxoSmithKlineINDUSTRY | 8 | Sep 3, 2025 | clinicaltrials |
| NCT02007512 | Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer | completed | Phase 2 | 247 | PfizerINDUSTRY | 7 | Sep 2, 2025 | clinicaltrials |
| NCT05323656 | A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) | completed | Phase 2 | 55 | Calliditas Therapeutics Suisse SAINDUSTRY | 7 | Sep 2, 2025 | clinicaltrials |
| NCT00777036 | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib | completed | Phase 2 | 133 | Bristol-Myers SquibbINDUSTRY | 18 | Aug 29, 2025 | clinicaltrials |
| NCT04607850 | Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions | completed | Phase 1 / Phase 2 | 108 | Barinthus BiotherapeuticsINDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT02923349 | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 87 | Incyte Biosciences International SàrlINDUSTRY | 4 | Aug 24, 2025 | clinicaltrials |
| NCT02998476 | A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) | completed | Phase 2 | 60 | Incyte CorporationINDUSTRY | 11 | Aug 22, 2025 | clinicaltrials |
| NCT03322540 | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | completed | Phase 2 | 154 | Incyte CorporationINDUSTRY | 18 | Aug 22, 2025 | clinicaltrials |
| NCT03597295 | A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) | completed | Phase 2 | 94 | Incyte CorporationINDUSTRY | 9 | Aug 21, 2025 | clinicaltrials |
| NCT05109442 | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | terminated | Phase 1 / Phase 2 | 112 | Affimed GmbHINDUSTRY | 5 | Aug 20, 2025 | clinicaltrials |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(STELLAR-305) | active not recruiting | Phase 2 / Phase 3 | 600 | ExelixisINDUSTRY | 26 | Aug 17, 2025 | clinicaltrials |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | completed | Phase 1 / Phase 2 | 307 | Incyte CorporationINDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT02872714 | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) | completed | Phase 2 | 263 | Incyte CorporationINDUSTRY | 11 | Aug 14, 2025 | clinicaltrials |
| NCT02924376 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) | completed | Phase 2 | 147 | Incyte CorporationINDUSTRY | 12 | Aug 14, 2025 | clinicaltrials |
| NCT04086264 | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 218 | AbbVieINDUSTRY | 6 | Aug 14, 2025 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials